10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE)

Recombinant Antibody
Catalog # APR10087

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P20273
Reactivity	Human
Clonality	ADC
Isotype	IgG4
Calculated MW	95348

Additional Information


Target/Specificity	Siglec-2 / CD22
Endotoxin Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information


Name	CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643}
Function	Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366).
Cellular Location	Cell membrane; Single-pass type I membrane protein

Tissue Location B-lymphocytes.


Images



The purity of Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE) is more than 95%, determined by SEC-HPLC.



The drug-to-antibody ratio (DAR) of the Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE) is 4.0.



Human Siglec-2 / CD22 HEK293 Cell Line were stained with Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.16 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.